Vaginal Infections and Other Conditions

Key Points

• Common vaginal infections include bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), each with distinct mechanisms and treatment pathways.
• Accurate diagnosis relies on focused symptom history plus targeted bedside/lab testing.
• Pregnancy and immunocompromised states alter risk and treatment safety choices.
• Nursing care emphasizes symptom relief, prevention education, and early recognition of complications.

Pathophysiology

Vaginal infections develop when normal protective vaginal ecology is disrupted or when fungal overgrowth occurs. BV reflects dysbiosis with reduced protective flora and increased anaerobic organisms, often presenting with thin discharge and characteristic odor. VVC reflects Candida overgrowth, often associated with hormonal shifts, diabetes, immunosuppression, obesity, pregnancy, or broad-spectrum antibiotic exposure.

For BV, common risk amplifiers include new or multiple partners, douching, inconsistent condom use, menstruation, and selected device/exposure contexts (for example copper IUD use). Treating asymptomatic male partners does not reliably reduce female recurrence. In perimenopause and menopause, low-estrogen vulvovaginal tissue change can increase irritation and may increase candidal-infection vulnerability in some patients.

Diagnostic differentiation is critical because therapies differ. BV uses antimicrobial regimens; VVC uses antifungal regimens. Mixed or recurrent patterns may require confirmatory tests and longer treatment courses. Routine asymptomatic BV screening is generally not recommended; symptom-triggered evaluation is preferred in most settings.

For VVC specifically, VVC is not an STI and routine partner treatment is generally not beneficial, except symptom-targeted topical care for balanitis in affected partners. If self-treatment fails or symptoms recur soon after treatment (for example within about 2 months), reassessment for alternative or complicated etiologies is needed.

Related conditions in this section include group B streptococcal colonization in pregnancy, where prevention of neonatal transmission is a core perinatal safety goal. GBS is not an STI pathogen, but untreated maternal colonization can lead to severe neonatal infection during vaginal birth.

Classification

• Bacterial dysbiosis condition: BV with elevated vaginal pH and clue-cell findings.
• Fungal overgrowth condition: VVC with pruritus, irritation, and curd-like discharge patterns.
• VVC severity subtype: Noncomplicated (infrequent, mild-moderate, likely C. albicans, immunocompetent host) versus complicated (recurrent/severe, non-albicans species, or diabetes/immunocompromised context).
• Pregnancy colonization condition: Group B streptococcal carriage requiring intrapartum management.
• Complication domains: Adverse pregnancy outcomes, reinfection, treatment intolerance, and STI co-risk overlap.

Nursing Assessment

NCLEX Focus

Prioritize distinguishing BV versus VVC based on symptom pattern, pH/wet prep data, and pregnancy/immunologic risk context.

• Assess discharge characteristics, odor, itching, burning, dyspareunia, and dysuria.
• Obtain exposure and risk history, including recent antibiotics, diabetes control, and immunosuppressive therapies.
• In VVC workup, assess for thick curd-like discharge, vulvar erythema/edema, and dysuria/dyspareunia patterns; use wet mount/KOH microscopy and culture when bedside diagnosis is uncertain.
• For recurrent/severe or immunocompromised-context VVC, escalate to culture or PCR to identify non-albicans Candida and guide longer non-fluconazole treatment pathways when indicated.
• In pregnancy care, verify GBS screening status (typically lower vaginal/rectal swab at 36-37 weeks) and allergy profile for intrapartum antibiotic selection.
• In pregnancy care, verify GBS screening status (typically lower vaginal/rectal swab at 36-38 weeks) and allergy profile for intrapartum antibiotic selection.
• Assess additional early-onset-neonatal-sepsis risk factors in GBS contexts (for example preterm labor, prolonged rupture of membranes, prior affected newborn, or chorioamnionitis).
• Review pregnancy status and gestational age before selecting medication options.
• In older adults with vaginitis symptoms, include concurrent assessment for vulvovaginal atrophy and genital neoplasia risk.
• Support diagnostic evaluation with point-of-care tests (pH, whiff, microscopy) and culture/PCR when indicated.
• Apply BV bedside criteria when available (Amsel framework: at least 3 of 4 findings such as thin homogeneous discharge, positive whiff test, clue cells on microscopy, and pH > 4.5).
• Screen for overlapping STI symptoms and need for broader reproductive infection workup.

Nursing Interventions

• Teach condition-specific treatment adherence, expected symptom trajectory, and when to return for reassessment.
• Counsel against douching and other practices that disrupt vaginal flora.
• For BV, reinforce regimen adherence across oral/intravaginal options (for example oral metronidazole, intravaginal metronidazole gel, or intravaginal clindamycin per order set) and symptom reassessment if persistence/recurrence occurs.
• Recommend comfort-focused symptom relief options such as cool compresses or sitz baths for itching and burning when appropriate.
• Reinforce condom considerations during topical/oil-based antifungal use.
• Reinforce BV relapse prevention: avoid douching, complete treatment, and use condoms during treatment; do not expect benefit from empiric treatment of asymptomatic male partners.
• Clarify partner considerations: routine treatment of asymptomatic AMAB partners is not generally indicated for BV, while AFAB partner transmission contexts can still occur and warrant individualized counseling.
• For VVC in pregnancy, emphasize topical antifungal preference and avoidance of oral fluconazole unless specifically directed by the treating clinician.
• Provide pregnancy-specific education, including safe medication selection and GBS screening implications.
• For positive or high-risk GBS contexts, reinforce intrapartum antibiotic timing/indications and communicate status clearly at the birth setting handoff.
• Coordinate follow-up for recurrent or complicated infection patterns.
• Provide vulvovaginal-health counseling (front-to-back wiping, gentle daily cleansing, avoiding tight occlusive clothing, and avoiding irritants such as deodorant products, excessive washing, and douching).

Self-Treatment Misclassification

Treating recurrent symptoms without diagnostic confirmation can miss resistant, non-albicans, mixed, or noninfectious causes.

Pharmacology

Drug Class	Examples	Key Nursing Considerations
Nitroimidazole antimicrobial	Metronidazole in oral or intravaginal BV treatment contexts	Reinforce full-course completion and avoid alcohol/propylene-glycol exposure during therapy and for 3 days after completion.
antifungal-medications (azole-antifungals)	Fluconazole and topical azoles for VVC	For uncomplicated VVC, single-dose oral fluconazole or topical azoles may be used by indication; in pregnancy, topical azoles are preferred and oral fluconazole is generally avoided.
penicillins	Penicillin/ampicillin intrapartum prophylaxis for GBS contexts	In pregnancy with indicated prophylaxis, verify allergy severity and susceptibility pathways for alternatives when high-risk beta-lactam allergy is present.

Clinical Judgment Application

Clinical Scenario

A pregnant patient at 30 weeks presents with recurrent malodorous thin discharge and self-treated repeatedly with over-the-counter antifungal products without improvement.

• Recognize Cues: Persistent symptoms despite antifungal use suggest non-candidal or mixed etiology.
• Analyze Cues: Misclassification may delay effective treatment and increase pregnancy-related risk.
• Prioritize Hypotheses: Priority is BV or mixed vaginitis requiring targeted diagnostics and pregnancy-safe treatment.
• Generate Solutions: Perform focused testing, initiate guideline-based therapy, and reinforce prevention counseling.
• Take Action: Escalate obstetric follow-up and monitor symptom response.
• Evaluate Outcomes: Symptoms resolve, recurrence risk decreases, and pregnancy safety is optimized.

Related Concepts

• sexually-transmitted-infections - Vaginal symptoms may overlap with STI syndromes and require differential testing.
• urinary-tract-infections - Dysuria and irritation can mimic urinary infection presentations.
• functional-reproductive-disorders - Hormonal changes can alter susceptibility and symptom patterns.
• culturally-competent-care - Sensitive, stigma-aware counseling improves adherence and follow-up.
• therapeutic-communication - Private and nonjudgmental communication supports accurate symptom disclosure.

Self-Check

1. Which findings most reliably distinguish BV from VVC at bedside?
2. Why is empiric repeated antifungal use risky without reassessment?
3. How does pregnancy status change vaginal-infection treatment decisions?